Pharmaceuticals News Today
Latest headline on this page:
2 headlines on Pharmaceuticals appeared in our news feed in the last 7 days with a measured price reaction attached. The largest measured reaction was -0.13% over 10 minutes on JNJ, after the headline at Oct 19, 08:02:55 ET. 2 more headlines have no measured move.
Price action when the news broke
08:02:55 ET
What moved — last 7 days
| Time | Ticker | Headline | 1 min | Reaction |
|---|---|---|---|---|
| Oct 19, 08:02:55 ET | JNJ | Johnson & Johnson (JNJ) plans to publish Tremfya findings covering 48‑week treatment in Crohn’s disease. | 0.00% | -0.13% · 10m |
| Oct 19, 08:00:01 ET | JNJ | Johnson & Johnson reports data showing Tremfya (guselkumab) was the only IL-23 treatment to deliver durable fistula remission through 48 weeks in Crohn’s disease with perianal fistula | 0.00% | -0.12% · 10m |
| Oct 19, 07:00:17 ET | BMY | At the ESMO conference, Bristol‑Myers Squibb (BMY) is set to present oncology data. | — | No measured move |
| Oct 19, 04:45:07 ET | LLY | In a Phase 3 trial for paediatric ulcerative colitis, Eli Lilly's (LLY) Omvoh achieved the primary endpoint of clinical remission; it is the first IL-23p19 inhibitor to report one-year Phase 3 results in this patient population. | — | No measured move |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Reaction pending means the measuring window for that headline is still open. Not attributed means the headline does not name the company the move was measured on, so we hold the number back. Times are New York ET. Headlines appear here 1 minute after they cross the live tape.
Our analysis
BioNTech Q2 2026: A 60% Revenue Collapse the Stock Didn't React To
Tuesday, Aug 4, 2026 · BioNTech reported second-quarter 2026 results on August 4, 2026.
Why Was BioNTech Stock Barely Moving on Aug 4, 2026?
Tuesday, Aug 4, 2026 · BioNTech's revenue fell roughly 60% and guidance was cut — but the stock didn't budge, because the market stopped valuing it on COVID vaccine sales a …